Whitepaper: Sterile formulation strategies to shorten timelines
Posted: 15 December 2021 | Thermo Fisher Scientific | No comments yet
This whitepaper reveals strategies to create simple, stable formulations for your sterile injectable, a solid foundation for your product’s lifecycle.
Lengthy early development timelines are common across new & emerging biotech companies for a multitude of reasons. Striking the right balance of speed, quality, risk, and investment allows you to shorten timelines and work with efficiency. Strategies adopted for a rapid development of a simple, yet flexible format proves beneficial. Download this whitepaper to learn how to adopt strategies that:
- Ensure consistent high oral solid dose
- Lay the foundation for commercial success.
Related content from this organisation
- Technical note: System precision in HPLC analysis of APIs and impurities
- Event review: The Future of QA/QC for Complex Biologics
- Application note: Achieve complete lab access with extended reality LIMS software
- Application Notes Supplement 2021
- Many hands make light work: why the new Bespoke Gene Therapy Consortium is a godsend for ambitious biopharma teams
Related topics
Biologics, Biopharmaceuticals, Drug Delivery Systems, Excipients, Formulation, Freeze Drying, Gene therapy, Good Manufacturing Practice (GMP), Ingredients, Manufacturing, Microbiology, Outsourcing, QA/QC, Regulation & Legislation, Research & Development (R&D), Stem Cells, Supply Chain, Vaccines
